1. Home
  2. NRIX vs USAS Comparison

NRIX vs USAS Comparison

Compare NRIX & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Americas Gold and Silver Corporation no par value

USAS

Americas Gold and Silver Corporation no par value

N/A

Current Price

$8.06

Market Cap

1.7B

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
USAS
Founded
2009
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Mining
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
NRIX
USAS
Price
$15.88
$8.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
2
Target Price
$29.46
$4.08
AVG Volume (30 Days)
844.9K
7.7M
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$76,987,000.00
N/A
Revenue This Year
N/A
$26.21
Revenue Next Year
$29.30
$129.30
P/E Ratio
N/A
N/A
Revenue Growth
99.31
N/A
52 Week Low
$8.18
$0.40
52 Week High
$22.50
$10.50

Technical Indicators

Market Signals
Indicator
NRIX
USAS
Relative Strength Index (RSI) 42.26 56.75
Support Level $15.62 $6.67
Resistance Level $19.98 $8.66
Average True Range (ATR) 0.78 0.62
MACD -0.03 -0.04
Stochastic Oscillator 36.46 71.70

Price Performance

Historical Comparison
NRIX
USAS

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About USAS Americas Gold and Silver Corporation no par value

Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.

Share on Social Networks: